New Delhi: Drug maker Pfizer is planning to extend its Corex brand to a series of new products to treat respiratory ailments as part of a revamp of its product portfolio.
The company has also decided to discontinue the manufacturing of current Corex cough syrup formulation.
"The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year," Pfizer said in a statement.
"The company has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation. Pfizer stands by the safety and efficacy of its current Corex Syrup formulation that has been duly approved by the central and state regulator," It added.
In March this year, Pfizer had discontinued manufacture and sale of its popular cough syrup Corex after the government banned fixed dose combination of Chlopheniramine Maleate+ Codeine Syrup.
According to Pfizer, with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place.
"Pfizer remains committed to provide a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex syrup formulation," it said.
Before the ban, Corex Cough Syrup had sales of Rs 244.48 crore in FY 2015-16.
The company has also decided to discontinue the manufacturing of current Corex cough syrup formulation.
"The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year," Pfizer said in a statement.
In March this year, Pfizer had discontinued manufacture and sale of its popular cough syrup Corex after the government banned fixed dose combination of Chlopheniramine Maleate+ Codeine Syrup.
Advertisement
"Pfizer remains committed to provide a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex syrup formulation," it said.
Advertisement
COMMENTS
Advertisement
Britain Fines Pfizer Record $107 Million For Huge Drug Price Hike Can You Buy Vicks Action 500, Corex? Delhi Court Verdict Today Big Pharma Vs Big Pharma In Court Battles Over Biosimilar Drugs Trainee IAS Officer Puja Khedkar Recalled To Academy, Training Put On Hold Under-Fire Trainee IAS Officer Accuses Pune Collector Of Harassment Meet Indian-Origin Usha Chilukuri Vance, Wife Of Trump's Vice President Pick Four In Five Americans Fear Country Is Sliding Into Chaos: Polls Royal Enfield Guerrilla 450 Launched In India; Prices Start At Rs. 2.39 Lakh Admission Deadline Extended For EWS And Special Needs Children Track Latest News Live on NDTV.com and get news updates from India and around the world.